Pazopanib Film-Coated Tablets (200 mg / 400 mg)
Healthy Inc is a specialized global supplier and exporter of advanced oncology, targeted antineoplastic, and high-potency therapeutics. We provide ultra-high-purity, kinetically stabilized Pazopanib Hydrochloride Film-Coated Tablets (200 mg / 400 mg), manufactured in WHO–GMP certified, dedicated HPAPI (High Potency Active Pharmaceutical Ingredient) cytotoxic isolation facilities. This “Multi-Target Tyrosine Kinase Inhibitor (TKI)” is an ultra-high-value, premium export to national oncology centers, specialized cancer hospitals, global health NGOs, and government health ministries in LATAM, the CIS, Africa, and Southeast Asia, serving as the globally mandated, life-extending intervention for advanced Renal Cell Carcinoma (RCC) and refractory Soft Tissue Sarcoma (STS).
Product Overview
This highly advanced formulation contains Pazopanib, a sophisticated targeted therapy that fundamentally outclasses older, highly toxic systemic chemotherapies. Instead of indiscriminately poisoning the body, it aggressively targets and disables the specific biological “switches” that tumors use to grow and survive.
The “Tumor Starvation & Angiogenesis” Specialist:
- Mechanism 1 (The Angiogenesis Blockade): Tumors cannot grow beyond a few millimeters unless they build their own blood vessel networks to steal nutrients from the body (a process called angiogenesis). Pazopanib aggressively blocks the Vascular Endothelial Growth Factor Receptors (VEGFR-1, -2, -3) and Platelet-Derived Growth Factor Receptors (PDGFR-alpha, -beta). By shutting down these receptors, it physically chokes off the tumor’s blood supply, starving the cancer cells to death.
- Mechanism 2 (The Multi-Kinase Strike): Beyond just starving the tumor, Pazopanib directly blocks the c-Kit and FGFR receptors on the surface of the cancer cells themselves, aggressively halting cell proliferation and division in highly aggressive, drug-resistant sarcomas.
- The Oral Oncology Advantage: Standard chemotherapy requires patients to spend days attached to IV drips in a hospital ward. Pazopanib is a potent, once-daily oral tablet, allowing patients with advanced, terminal cancers to manage their disease at home, drastically improving their quality of life and freeing up critical oncology ward beds.
Product Composition & Strength
We supply this product as a Precision-Engineered, High-Density Film-Coated Tablet, packed exclusively in highly secure, child-resistant heavy-gauge HDPE bottles or specialized Alu-Alu blister strips to ensure the absolute chemical stability of the cytotoxic molecule and prevent accidental exposure.
| Active Ingredient | Strength | Primary Clinical Function |
|---|---|---|
| Pazopanib HCl INN/Ph.Eur. | 200 mg (Base Equivalent) | Dose-Modification Standard: Essential unit for precise dose reduction in patients experiencing severe hepatic toxicity or adverse drug reactions. |
| Pazopanib HCl INN/Ph.Eur. | 400 mg (Base Equivalent) | Global Clinical Standard: Primary therapeutic unit designed to achieve the massive 800 mg daily protocol with minimal pill burden. |
| Excipients | Microcrystalline Cellulose / Sodium Starch Glycolate / Povidone K30 / Magnesium Stearate / Hypromellose / Titanium Dioxide | Diluent / Superdisintegrant / Binder / Lubricant / Premium Cytotoxic-Barrier Film-Coating (Engineered specifically to seal the lethal HPAPI inside the tablet, completely protecting healthcare workers and caregivers from highly toxic dust exposure) |
*Pack Sizes: Bottles of 30 or 60 Tablets (Optimized specifically for strict 30-day chronic oncology dispensing regimens).
Technical & Logistics Specifications
Critical data for Pharmaceutical Importers, Oncology Distributors, and Hospital Procurement Boards.
| HS Code | 3004.90.39 (Medicaments containing other active substances – Antineoplastics / Targeted Therapies) |
| CAS Number | 635702-64-6 (Pazopanib Hydrochloride) |
| Dosage Form | Film-Coated Tablet (Immediate Gastric Release) |
| Packaging | Desiccant HDPE Bottles or Alu-Alu Blisters (STRICTLY MANDATORY). Ensures the absolute stability of the formulation across Zone IVb tropical climates while meeting international hazardous drug transport protocols. |
| Storage | Store strictly below 30°C in a dry place. Protect from Light. Handle with cytotoxic protocols. |
Manufacturing Authority
Marketed and Distributed by Healthy Inc from WHO-GMP & ISO 9001:2015 certified units.
- Dedicated HPAPI Oncology Isolation Engineering (CRITICAL COMPLIANCE): Pazopanib is a highly potent antineoplastic agent. It cannot be manufactured in a standard facility. Our production occurs in a completely segregated, multi-million-dollar Oncology Block. We utilize strict negative-pressure cleanrooms, closed-loop barrier isolators (glove boxes), and advanced multi-stage HEPA filtration systems. This guarantees zero cross-contamination with general medicines and provides absolute, life-saving protection for our pharmaceutical engineers against systemic cytotoxic absorption.
Therapeutic Indications (Human Use)
Indicated for the targeted management of severe, advanced oncological malignancies:
- Advanced Renal Cell Carcinoma (aRCC): First-line treatment of patients with advanced and/or metastatic renal cell carcinoma.
- Advanced Soft Tissue Sarcoma (aSTS): Treatment of patients with advanced soft tissue sarcoma who have received prior chemotherapy (efficacy is primarily demonstrated in non-adipocytic sarcomas).
Dosage & Administration
Recommended Dosage (Strictly as per Medical Oncologist Guidelines):
- Standard Adult Dosing: The recommended dose is 800 mg taken orally once daily.
- Administration (THE EMPTY STOMACH RULE – CRITICAL): Pazopanib MUST be taken without food (at least 1 hour before or 2 hours after a meal). Taking this drug with a high-fat meal doubles the systemic absorption (AUC), leading to a massive, potentially fatal overdose and lethal liver toxicity.
- The Intact Tablet Rule: Tablets must be swallowed completely whole with water. They must never be broken, crushed, or chewed, as this destroys the protective film coating and exposes the patient and caregivers to hazardous cytotoxic dust.
Safety Warnings (CRITICAL Regulatory & Clinical Data):
- BLACK BOX WARNING (Severe and Fatal Hepatotoxicity): Pazopanib can cause severe, sudden, and fatal liver failure. Serum liver tests (ALT, AST, and bilirubin) must be monitored before initiation of treatment and at least once every 4 weeks for the first 4 months of treatment.
- Cardiovascular Toxicity & QT Prolongation: Severe and fatal cardiovascular events, including myocardial infarction, ischemic stroke, and massive spikes in blood pressure (hypertensive crisis) have been observed. It can severely prolong the QT interval; baseline and periodic ECGs are mandatory.
- Hemorrhagic Events & GI Perforation: By attacking blood vessels (anti-angiogenesis), Pazopanib severely weakens the lining of the stomach and intestines, leading to fatal gastrointestinal perforation, fistulas, and severe internal hemorrhage.
- CYP3A4 Drug Interactions (Absolute Contraindication): Pazopanib is heavily metabolized by CYP3A4. Concomitant use with strong CYP3A4 inhibitors (like Ketoconazole or Ritonavir) will cause massive, toxic accumulation of the drug, requiring immediate dose reduction to 400 mg.
Global Export & Contract Manufacturing Services
Healthy Inc stands as a premier Pharmaceutical Exporter in India, dedicated to serving international Pharma Traders, Wholesalers, and National Oncology Networks. As a verified Medicine Supplier in Mumbai, we offer flexible Third Party Manufacturing (Contract Manufacturing) services for Advanced Targeted Therapies and High-Potency Antineoplastics. Whether you are looking for a reliable Government Tender Supplier for cancer hospitals in Africa or a B2B Pharma Marketplace partner for Latin America, our logistics network ensures timely, secure delivery of highly regulated, WHO-GMP certified oncology products.